Health TrialsbyHealthPanel

Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors

ConditionsAdvanced Solid TumorsCholangiocarcinoma
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
AgeNot listed
SponsorTransThera Sciences (Nanjing), Inc.

About this trial

This study is an open-label, multicenter study for Continued Characterization of Safety and Tolerability of TT-00420 (tinengotinib) Tablet Monotherapy in Adult Patients with Advanced Solid Tumors

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Subject is currently enrolled in a pre-defined TransThera-sponsored parent study and is receiving tinengotinib as a single agent.

Subject is currently deriving clinical benefit from the study treatment, as determined by the investigator.

Disqualifiers

Subject has been permanently discontinued from tinengotinib in the parent protocol for any reason other than enrollment in the Rollover study

Subject does not meet the criteria specified in the parent protocol for continued treatment on study.

Trial design

Treatments tested in this trial

  • Tinengotinib

    Drug

    Subjects on this rollover study may continue to receive tinengotinib at the dose that they were previously receiving on the TransThera parent study. Dose may be decreased by one dose level from the previously-received dose upon study entry, based on physician discretion.

Treatment groups

No treatment groups listed

Trial outcomes

This trial has no outcomes listed.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

TransThera Sciences (Nanjing), Inc.

Lead sponsor

Source ClinicalTrials.gov
Apply now